Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Summary

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

Eligibility

Inclusion Criteria:

* 18 years of age or older
* Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
* One of the following:

  * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
  * Completed chemotherapy with no cardiotoxicity at least two years post treatment
  * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
* An understanding of the protocol and its requirements, risks, and discomforts
* The ability and willingness to sign an informed consent

Exclusion Criteria:

\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol

Conditions3

Locations4 sites

Browse More Trials